安圭定（NSC 141537）在结直肠癌5天疗程中的II期评估。一项东南癌症研究组试验。
Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group Trial.
作者信息
DeSimone P A, Greco F A, Lessner H F, Bartolucci A
出版信息
Am J Clin Oncol. 1986 Jun;9(3):187-8. doi: 10.1097/00000421-198606000-00002.
Abstract
Thirty-three patients with advanced colorectal adenocarcinoma were treated with daily Anguidine i.v. 5 mg/m2 X 5 for 3 weeks. The patients were stratified into two groups: prior chemotherapy and no prior chemotherapy. No responses were noted. Major toxicities were hypotension and fever.
摘要
33例晚期结肠腺癌患者接受静脉注射安吖啶治疗，剂量为5mg/m²，每日一次，共5天，持续3周。患者被分为两组：曾接受化疗组和未接受过化疗组。未观察到缓解情况。主要毒性反应为低血压和发热。
Zotero 插件